Crinetics (CRNX) Director Vivaldi Coelho Rogerio Sells Shares

What Happened

• Vivaldi Coelho Rogerio, a director of Crinetics Pharmaceuticals (CRNX), disposed of common stock and converted equity awards into cash on Sept. 1, 2026, in connection with the Vertex merger. Reported proceeds sum to approximately $6,860,683.
• Transactions include direct cancellation of common shares (13,300 and 5,925 shares) paid at $85.00/share, and cash settlements for restricted stock units and stock options (various share counts and per-share cash amounts shown) as described in the filing.

Key Details

• Transaction date: 2026-09-01 (Effective Time of Merger).
• Reported line items and proceeds:
  • 13,300 shares @ $85.00 = $1,130,500 (common stock)
  • 5,925 shares @ $85.00 = $503,625 (common stock)
  • 35,000 option/derivative shares @ $56.69 = $1,984,150
  • 8,750 option/derivative shares @ $66.71 = $583,713
  • 17,500 option/derivative shares @ $64.68 = $1,131,900
  • 12,500 option/derivative shares @ $40.29 = $503,625
  • 10,350 option/derivative shares @ $52.67 = $545,135
  • 9,730 option/derivative shares @ $49.13 = $478,035
• Total cash received (approx.): $6,860,683.
• Shares owned after transaction: Reported/common implication — the reported instruments were cancelled/converted in the merger; the filing reflects cash-out treatment rather than retained shares.
• Notable footnotes:
  • F1–F4: Transactions resulted from the Agreement and Plan of Merger with Vertex (effective Sept. 1, 2026). Outstanding RSUs vested immediately and were converted to cash equal to $85.00 per share less tax withholding (F2). Stock options with exercise prices below $85 were cashed out for the difference between $85 and the exercise price (F3/F4); options at or above $85 would have been cancelled for no consideration.
  • Cash amounts are reported net of any applicable tax withholdings.
• Filing timeliness: Reported for the period 2026-09-01; no late filing indicated.

Context

• These dispositions are merger-related cash settlements (disposition to issuer), not open-market sales. That means the insider did not necessarily "sell" on the market but received the merger consideration per the merger agreement.
• For retail investors: merger cash-outs remove these shares and awards from future insider holding metrics; purchases are generally more informative about insider conviction, while merger cash settlements are routine outcomes of an acquisition.